Navigation Links
Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO

) (2-methoxyestradiol or 2ME2), the Company's lead drug candidate, is currently in multiple Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell-cycle regulator, is in various Phase 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's website at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical tria
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader ... cell immunotherapy to treat a variety of cancers, today ... by BVCF, a China -based healthcare ... immunotherapy company focused on the development of new therapeutics ... with Shanghai Cancer Institute and Shanghai Renji Hospital, the ...
(Date:11/26/2014)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... by IQ4I Research and Consultancy focusing on the active ... about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Ingredients Global Market – Forecast to 2020 ...
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3
... SRI International, an independent nonprofit research and development organization, ... Sarnoff Corporation, its wholly owned subsidiary in Princeton, New ... welcome our new colleagues to SRI and celebrate their ... Carlson, Ph.D., president and CEO of SRI International. "Together, ...
... 3, 2011 Centre Partners Management LLC ("Centre Partners"), a ... York and Los Angeles, today announced the completion of the ... of Troy Limited (Nasdaq: HELE). Kaz is an international leader ... is valued at $260 million subject to certain closing working ...
Cached Medicine Technology:Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 2Centre Partners Announces Successful Realization of Investment in Kaz, Inc. 3
(Date:11/27/2014)... Nov. 26, 2014 (HealthDay News) -- Most babies and ... cold, the U.S. Food and Drug Administration says. ... given to children younger than 2 because they could ... warned. American adults average about three colds a ... get a cold, parents might want to give them ...
(Date:11/27/2014)... (HealthDay News) -- Thanksgiving meals can pose a challenge ... an expert says. Many traditional Thanksgiving dishes -- ... -- are gluten-free, but "when it comes to pies, ... considered," Dr. Anca Safta, director of the Gluten and ... Center in North Carolina, said in a center news ...
(Date:11/27/2014)... York, NY (PRWEB) November 27, 2014 The ... to offering stylish, comfortable and high functioning compression socks, are ... The newly-released socks use an innovative Gradient Pressure (TM) knitting ... oxygenated blood. , VIM & VIGR’s commitment to adding flair ... of as just functional recently caught the eye of a ...
(Date:11/27/2014)... 27, 2014 Now that Thanksgiving is ... officially launched, Emassagechair.com has announced its eagerly ... Event. , Negotiating on behalf of their customers, ... chair brands, Emassagechair.com has generated significant buzz in the ... biggest discounts yet. , Shoppers are excited for significant ...
(Date:11/27/2014)... CA (PRWEB) November 27, 2014 Two ... dental implants procedure will help one person with ... , Dr. Saj Jivraj and Dr. Mamaly Reshad of ... Hills, Calif., have launched a website devoted to helping ... section of the website would be devoted to helping ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5
... by researchers at Columbia University Medical Center to analyze ... to cancer treatment, //it has been found that nearly ... More specifically, stage III colon cancer patients who were ... months, were found to stop their treatment before completion. ...
... workers frequently report sick due to respiratory problems, and ... develop// occupational asthma every year. Prolonged exposure to dust ... ,Alveolitus or 'occupational asthma’ is triggered by constant ... of the lung. It is said that the ...
... Mali in West Africa, which is said to be naturally ... according to scientists//. , ,A team including researchers from ... US-based institutes said they have also identified a gene that ... to infection by the parasite, reported the online edition of ...
... of Celebrex was $3.3 billion worldwide. But after widespread concerns ... But 16 months later the has returned to the consumer ... which plunged last year during the ad moratorium. Now the ... ingredients that could boost it sales. Each ad includes ...
... Pacific Northwest National Laboratory, scientists have developed a new ... levels. They have taken a polymer (protein) and layered ... capacity. ,This configuration can accommodate a wide ... detection, said Yuehe Lin, who led the research at ...
... late 1950s was later discarded as a stunt. However recent ... the one who pioneered this in 1957. He claimed that ... a second actually bought the advertised product. He had tested ... his results in the tests they had conducted. Vicary later ...
Cached Medicine News:Health News:Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy 2Health News:Polymer Molecule Layered On Carb Molecule to Increase Sensitivity 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: